Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05418244 · ClinicalTrials.gov registry record · Phase 2
Inhaled Isopropyl Alcohol for Treatment of Nausea
A Phase 2 study of Nausea and Vomiting, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT05418244 is a Phase 2 study of Nausea and Vomiting that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 84 participants, below the 239-participant average among 17 other Nausea trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05418244, a Phase 2 study of Nausea and Vomiting, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the efficacy of inhaled isopropyl alcohol in treating nausea/vomiting among pediatric patients compared with the conventional ondansetron, or placebo treatment in a tertiary care pediatric emergency department.
Conditions Studied
Interventions
- OTHER Inhaled Isopropyl Alcohol
- DRUG Oral Ondansetron
- OTHER Inhaled Placebo
Study Locations (1)
New York
- Oishei Children's Hospital - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05418244
The ClinicalTrials.gov registry entry for NCT05418244 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 17 other Nausea trials with a reported enrollment target (65% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Nausea appearing as the primary indexed condition, and to 3 interventions - of which Inhaled Isopropyl Alcohol is the first listed.
NCT05418244 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05418244 about?
NCT05418244 is a clinical study titled "Inhaled Isopropyl Alcohol for Treatment of Nausea". To determine the efficacy of inhaled isopropyl alcohol in treating nausea/vomiting among pediatric patients compared with the conventional ondansetron, or placebo treatment in a tertiary care pediatric emergency department.
What is the current status of trial NCT05418244?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2022-04-20. Estimated completion is 2026-06-30.
What conditions does trial NCT05418244 study?
This clinical trial studies the following conditions: Nausea, Vomiting, Children, Only.
What interventions are being tested in trial NCT05418244?
The interventions under investigation include: Inhaled Isopropyl Alcohol (OTHER), Oral Ondansetron (DRUG), Inhaled Placebo (OTHER).
Who is sponsoring clinical trial NCT05418244?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05418244 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
RECRUITING · Phase 2
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
COMPLETED · Phase 2
-
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting
RECRUITING · NA
-
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.